Human Kallikrein-4(KLK4) ELISA kit

1. During the descriptive analysis, the variables ethnicity, biofilm, and gingivitis and the markers rs2242670 and rs2978642 were statistically significant. In the multivariate analysis, the marker rs2242670 and the variable biofilm maintained statistical significance. Genetic variations in the KLK4 gene may contribute to dental decay. PMID: 28445870
2. Epithelial-derived KLK4 promotes tumour progression by actively promoting cancer-associated fibroblasts differentiation in the prostate stromal microenvironment. PMID: 28510269
3. structural analysis of mechanism of KLK4 inhibition PMID: 27767076
4. These findings prompt a new mechanistic model and line of enquiry into the role of KLK4 in enamel hardening and malformation. PMID: 29229389
5. Results show that AMTN and KLK4 are not essential for biological processes outside of the dentition or during the secretory stage of amelogenesis. Both KLK4 and AMTN proved to be essential for the maturation of dental enamel, a process that requires the removal of extracellularmatrix proteins and the deposition of ions on the sides of enamel crystallites. PMID: 26620968
6. The KLK4 protein is localized in the cytoplasm of tumor and stroma cells. PMID: 28755528
7. KLK4 as a potential multifunctional regulator of prostate cancer progression. PMID: 27378148
8. Low KLK4 expression is associated with lupus nephritis. PMID: 26546590
9. KLK4 may contribute to the metastasis of OSCC through the PI3 K/AKT signaling pathway PMID: 28743213
10. KLK4 acts as an oncogene in OSCC cells, and targeting KLK4 may be a promising method for OSCC therapy. PMID: 28150891
11. Studied a 70-kb region surrounding KLK4 in East Asian population; found within combined unusual low levels of diversity, high frequency variants with significant levels of population differentiation. PMID: 26420451
12. secreted into the extracellular microenvironment by neutrophils stimulated with bioactive mediators PMID: 25563717
13. Novel homozygous mutations in the KLK4 (c.620_621delCT, p.Ser207Trpfs*38) were identified in amelogenesis imperfecta consanguinity. Mutant KLK4 was degraded intracellularly and became inactive. PMID: 26124219
14. this study provides supportive evidence in favor of a prognostic value for KLK4 in OSCC and suggests that KLK4 could serve as a potential therapeutic target in patients with oral cancer. PMID: 25862839
15. Human ephrin-B2 is poorly cleaved by KLK4 while the homologous mouse is not. PMID: 25724897
16. miR-378 was predicted to target both KLK2 and KLK4 and downregulated levels detected in prostate cancer patients. PMID: 25153390
17. The differential regulation of alternative transcripts (using KLK2, KLK3 and KLK4 as models) by androgens and anti-androgens as an indicator of prostate cancers, was investigated. PMID: 25153393
18. KLK4 mRNA positivity could be regarded as a novel independent indicator of favorable prognosis for the disease-free survival of laryngeal squamous cell carcinoma patients. PMID: 24854539
19. The variant rs1722561 of Kallikreins might reduce the risk of sporadic intracranial aneurysms among individuals of Chinese Han ethnicity. PMID: 24405067
20. These results demonstrate that the activities of AR and mTOR pathways are maintained by KLK4, which may thus be a viable target for therapy PMID: 23798432
21. Survival analysis demonstrated that KLK4 mRNA expression constitutes an unfavorable prognostic biomarker in colorectal adenocarcinoma, predicting poor disease-free survival (DFS), independently of the nodal status and tumor size. PMID: 23201139
22. amelogenesis imperfecta-causing mutations were identified in three of the probands: 1) a novel single-nucleotide deletion in both KLK4 alleles (g.6930delG; c.245delG; p.Gly82Alafs*87) that shifted the reading frame. PMID: 23355523
23. findings provide suggestive evidence of a role for genetic variation in the KLK4 locus in prostate cancer predisposition PMID: 22970239
24. signal peptide induces cytotoxic T cell responses in healthy donors and prostate cancer patients PMID: 21874303
25. Complex gene expression at the KLK4 locus that might be a hallmark of cis sense-antisense chimeric transcription in prostate cancer cells. PMID: 20406994
26. KLK4 is upregulated in early-stage but not late-stage prostate cancer. PMID: 20180634
27. KLK4 signaling via PAR1 may represent a novel pathway in colon tumorigenesis. PMID: 20056842
28. Kallikrein 4 overexpression is associated with endometrial carcinoma. PMID: 20009893
29. Prostate cancer cells exhibit a novel double-paracrine mechanism whereby cancer epithelium produces KLK4 to activate PAR-1 in the surrounding stroma, in-turn releasing cytokines that stimulate cancer cells to proliferate & increase production of KLKs. PMID: 19795418
30. The demonstration that KLK4-specific CD4 T cells exist in the peripheral circulation of normal male donors supports the use of KLK4 in whole gene-, protein-, or peptide-based vaccine strategies against prostate cancer. PMID: 12077288
31. KLK4 has a unique structure and function compared with other members of the KLK family and may have a role in the biology and characterization of prostate cancer. PMID: 15059887
32. A novel human kallikrein mutation associated with a rare autosomal recessive form of amelogenesis imperfecta. PMID: 15235027
33. Human kallikrein 4, in particular, and prostate specific antigen, have a functional role in the progression of prostate cancer through their promotion of tumour cell migration. PMID: 16172196
34. There are two major isoforms of hK4 (KLK4-254/hK4-254 and KLK4-205/hK4-205) expressed in prostate cancer with different regulatory and expression profiles that imply both secreted and novel nuclear roles. PMID: 16322328
35. Here we demonstrate uPAR is a target for tissue kallikrein 4[hK4], cleaved in the D1-D2 linker and D3 domain. hK4 may modulate tumor-associated uPA/uPAR activity by activating the pro-enzyme form of uPA or cleaving the cell surface-associated uPA receptor PMID: 16497155
36. Design of serpin fragments as highly specific inhibitors of human kallikrein 14. PMID: 16704423
37. an investigation of its enzymatic properties regarding substrate preference, degradation of extracellular matrix proteins, and its inhibition by various inhibitors PMID: 16800736
38. hK4 expression and interaction with both tumor cells and osteoblasts suggests a role for hK4 in prostate cancer bone metastasis PMID: 17221837
39. KLK4 protein is significantly overexpressed in malignant prostate compared with normal prostate. KLK4 expression is predominantly in the nucleus of basal cells in the prostate epithelium in keeping with its distribution in prostate cancer cells in vitro. PMID: 17545602
40. KLK4 and KLK5 activate pro-HGFA. PMID: 18221492
41. These data provide insight into KLK4-mediated cell signaling and suggest that signals induced by this enzyme via protease-activated receptors may be important in prostate cancer. PMID: 18308730
42. Recombinant hK4 activates ERK1/2 signaling of prostate cancer cell lines, which express both PAR1 and PAR2. PMID: 18567807
43. KLK4 may be associated with the development and progression of breast cancer and suggest its potential use in breast cancer monitoring. PMID: 18687310
44. KLK4 gene expression may be used as a new potential biomarker in breast cancer. PMID: 19190825
45. In a family with a hypomaturation-type enamel defect, mutational and haplotype analyses revealed no mutations in the KLK4 gene. PMID: 19966041

Show More

Hide All

HGNC: 6365

OMIM: 204700

KEGG: hsa:9622

STRING: 9606.ENSP00000326159

UniGene: Hs.218366